FDA meets with PCAC: peptides in
review
Seven peptide-related bulk drug substances are under review for compounding. Here's what happened, what the FDA recommended, and how it may impact your practice.
Watch the meetings live
Stay up to date with us
Thursday, July 23 meeting
Friday, July 24 meeting
What the meeting is about
Key topics between the FDA and PCAC
On July 23–24, 2026, the FDA’s Pharmacy Compounding Advisory Committee (PCAC) met to review seven peptide-related bulk drug substances being considered for potential inclusion on the Section 503A Bulks List.
FDA recommended against adding any of the seven peptides to the 503A Bulks List — citing concerns about safety, effectiveness, characterization, and data quality.
The meeting let the Committee weigh that analysis, nominator input, and public comment before voting on each substance.
Substances under review
The seven peptides — and the uses evaluated
What this means for providers
Evaluate each substance on its own merits
The July meeting is an important development in the evolving regulatory landscape around peptide compounding. Avoid interpreting it as a single decision affecting all peptides — the immediate implications depend on the recommendation for each individual substance and any subsequent FDA action.
About Southend Pharmacy
An established 503A pharmacy, built on transparency
Southend Pharmacy is rooted in supporting providers and patients with compounded solutions and transparency as regulatory guidance evolves. Our team is closely following the regulatory review of peptide-related bulk drug substances and developments after the July PCAC meeting. We are committed to helping providers understand:
- What FDA recommended going into the meeting
- How PCAC voted on each substance
- Where PCAC recommendations align with or differ from FDA's position
- What subsequent developments may mean for patient-specific compounding
Discuss a path forward with Southend Pharmacy
Questions about the July PCAC meeting, the recommendations for specific peptide-related bulk drug substances, or how evolving guidance may relate to your practice? Speak with one of our Account Managers.
New to Southend? Book a call with our account management team by clicking here:
Already a partner with Southend? For more information call your dedicated account manager here:
PCAC provides advice and recommendations as part of the FDA regulatory review process. PCAC recommendations are advisory and non-binding and should not be interpreted as FDA approval of a bulk drug substance, compounded drug preparation, or therapeutic use.